Opinion
19hOpinion
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
Science must guide treatment decisions, and healthcare practitioners must take decisive action now to stop inappropriate fibrate prescribing for cardiovascular risk reduction, especially on top of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback